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lobally,  whooping  cough  (pertussis)  is  still  an  important
ause of  death  in  infancy  and  continues  to  be  a  public
ealth concern  even  in  countries  with  high  vaccination  cov-
rage. In  2008,  over  80%  of  all  infants  worldwide  received
hree doses  of  pertussis  vaccines.1 Despite  this,  15  million
ertussis cases  occurred  worldwide,  95%  of  them  in  devel-
ping countries,  and  about  200,000  children  died  from  the
isease.1
The  causative  agent  of  whooping  cough,  Bordetella  per-
ussis, was  isolated  about  one-hundred  years  ago.  Before
he development  of  the  killed  whole-cell  vaccine  and  the
mplementation of  mass  immunizations  in  the  1950’s,  per-
ussis was  the  main  cause  of  infant  mortality.2 Thereafter,
he incidence  of  whooping  cough  in  vaccinated  infants  and
oung children  has  dropped  dramatically.  Vaccinations  were
mplemented  in  most  countries  and  the  programs  were  suc-
essful, but  increasing  publicity  was  focused  on  the  adverse
eactions.3
Due  to  increasing  risk  of  adverse  reactions  by  age  and
y vaccination  times  using  the  whole-cell  vaccine,  and  less
everity of  whooping  cough  in  older  children,  vaccinations
ere in  most  programs  not  given  after  the  age  of  24  months.
herefore, previously  vaccinated  children  became  again
usceptible to  pertussis  at  school  age,  and  the  incidence
f pertussis  increased  particularly  in  school  children.  Of
ourse, an  increased  awareness  about  pertussis  risk  and  an
ncreased use  of  diagnostic  tests  for  pertussis  inﬂuenced
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he  reported  rates.4 The  clinical  picture  in  the  earlier  vac-
inated children  at  school  age  was  long-term  cough,  not
ough with  severe  spells  or  whooping  attacks  as  seen  in
on-vaccinated children.  The  coughing  school  children  were
ot  necessary  diagnosed  as  pertussis  cases,  and  they  fur-
her transmitted  the  B.  pertussis  bacterium  to  the  infants
ithin the  families.  During  the  two  last  decades  of  1900’s,
any parents  refused  the  pertussis  vaccination,  and  the
ncidence of  whooping  cough  again  started  to  increase  in
nfants.3
Thus,  there  was  an  urgent  need  for  a  new  pertussis  vac-
ine containing  puriﬁed  antigens  instead  of  killed  whole
acteria with  less  adverse  reactions  and  with  a  possibility
o vaccinate  all-aged  children.  Acellular  pertussis  vaccine,
njected jointly  with  toxin-based  vaccines  to  diphtheria
nd tetanus,  was  introduced  in  1981-1989  in  Japan,  and
n 1991-1996  in  most  other  countries.3 After  the  introduc-
ion of  the  new  acellular  pertussis  vaccine,  the  booster
accinations have  been  extended  up  to  the  age  of  14-16
ears in  most  countries.  In  future,  pertussis  may  trans-
er to  young  adults,  that  is  to  the  mothers  and  fathers  of
oung infants,  and  the  vaccinations  of  young  adults  may  be
equired.5
The  development  of  new  techniques  for  viral  and  bac-
erial infections,  ﬁrstly  direct  viral  antigen  detection  by
mmune ﬂuorescence  or  enzyme  immune  assays,  and  sub-
equently direct  viral  or  bacterial  genome  detection  by
olymerase chain  reaction  (PCR),  have  open  a new  time
or research  of  respiratory  infections.  These  new  tech-
iques have  changed  the  one-agent-one  infection  concept
n microbial  etiology  of  respiratory  infections.  Not  only
ultiple ﬁndings,  but  also  multiple  etiologies  may  be
ommon in  respiratory  infections,  including  mixed  viral-
iral, mixed  viral-bacterial  and  mixed  bacterial-bacterial
nfections.6
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The  observation  that  B.  pertussis  and  certain  viruses,
especially respiratory  syncytial  virus  can  cause  concomitant
respiratory infections  is  30  years  old.7 Recent  Finnish  studies
have conﬁrmed  that  about  10%  of  non-vaccinated  or  partially
vaccinated infants  hospitalized  for  bronchiolitis  at  age  less
than 6  months  with  no  suspicion  of  pertussis,  have  mixed
RSV and  B.  pertussis  infections.8,9 When  the  hospital  records
were analyzed  retrospectively,  the  clinical  pictures  did  not
differ  between  B.  pertussis  positive  and  negative  cases.
In  this  issue  of  the  journal,  Ferronato  et  al.  publish
their observations  on  viral  infections  in  67  Brazilian  infants
admitted for  suspected  pertussis  at  the  average  age  of  2.0-
2.5 months.10 PCR  for  B.  pertussis  was  positive  in  44%  and
immune ﬂuorescence  for  respiratory  viruses  (mainly  RSV)
in 26%.  Both  B.  pertussis  and  some  virus  were  identiﬁed  in
5% of  the  children.  Cough  followed  by  inspiratory  stridor  or
cyanosis, as  well  as  leukocytosis  and  lymphocytosis  in  blood
predicted pertussis,  whereas  rhinitis  and  dyspnea  predicted
viral etiology.
In accordance,  there  is  some  evidence  from  earlier  stud-
ies, that  clinical  features,  such  as  age,  presence  of  cough
and absence  of  dyspnea,  may  be  useful  to  separate  B.
pertussis from  viruses  in  young  children  with  respiratory
infection. Among  141  North-American  infants  hospitalized
for suspected  pertussis,  PCR  was  positive  for  B.  pertussis
in 15%,  and  in  retrospective  analyses,  the  positive  infants
were younger  and  presented  with  lower  respiratory  rate
and higher  blood  lymphocyte  counts.11 Among  126  English
children aged  less  than  5  months  treated  in  the  pediatric
intensive care  unit  for  respiratory  infection,  PCR  or  serology
was positive  for  B.  pertussis  in  20%,  and  in  retrospec-
tive analyses,  the  B.  pertussis-positive  infants  presented
with longer  duration  of  cough,  more  apneas,  more  cough-
ing spells,  and  higher  blood  lymphocyte  counts.12 Mixed
RSV-pertussis infection  was  present  in  36%  of  B.  pertussis-
positive cases.  In  all,  126  French  children  aged  less  than  4
months were  recruited  in  a  prospective  study,  and  PCR  was
positive for  B.  pertussis  in  16%,  and  the  positive  and  negative
infants differed  signiﬁcantly  only  for  the  presence  of  cough-
ing spells.13 Mixed  pertussis-RSV  infection  was  identiﬁed  in
12%.
Ferronato et  al.  concluded  that  the  etiological  diagnosis
of viral  infection  by  PCR  may  enable  the  reduction  of  the  use
of  antibiotics,  especially  that  of  macrolides,  for  suspected
but non-proved  pertussis  cases.10 Of  course  this  is  true,  but
the beneﬁts  are  marginal.  In  addition,  the  identiﬁcation
of RSV  or  other  respiratory  viruses  does  not  rule  B.  per-
tussis infection  out,  since  mixed  infections  are  common.8,9
Moreover,  PCR  is  so  sensitive  that  false-positive  ﬁndings  are
possible, reﬂecting  for  example  previous  infection  or  clin-
ically insigniﬁcant  temporary  carriage.  When  pertussis  in
young children  is  considered,  under-treatment  may  be  a
more severe  problem  than  over-treatment,  since  pertus-
sis may  be  severe,  even  fatal  in  non-vaccinated  or  partially
vaccinated infants.14 The  bulk  of  the  misuse  of  antibiotics
comes from  the  treatment  of  common  colds  and  other
mild upper  respiratory  infections  with  antibiotics,  including
overtreatment of  suspected  acute  otitis  media  with  broad-
spectrum antibiotics.
A  recent  Cochrane  review,  updated  in  2011,  included
13 clinical  studies  on  the  role  of  antibiotics  in  whooping
cough, and  the  authors  concluded  that  azithromycin  and521
larithromycin  are  equally  effective  as  erythromycin  in  the
radication of  B.  pertussis  from  the  airways  of  children.15
linical  experience  suggests  that  macrolides  relieve  the
ymptoms of  whooping  cough  in  infants  but  not  in  older
hildren. However,  the  research  evidence  for  the  effect
f antibiotic  therapy  is  mainly  lacking  or  is  negative  even
n infants.15 The  differences  in  clinical  responses  between
nfants and  older  children  comes  from  the  duration  of  B.
ertussis involvement,  and  thus,  from  the  degree  of  air-
ay damage.  When  damage  has  developed  for  weeks  and
he symptoms  are  non-speciﬁc,  inﬂammatory  disorders  like
sthma are  merely  suspected  than  acute  infections.  Treat-
ent with  macrolides  prevents  the  spread  of  B.  pertussis
ithin the  families,  though  research  data  on  this  is  also
canty, old  and  based  on  trials  with  erythromycin  only.16,17
Whooping  cough  is  --  one-hundred  years  after  the  iden-
iﬁcation of  the  causative  bacteria,  seventy  years  after  the
tart of  the  vaccination  of  infants  using  whole  cell  vaccine,
nd twenty-ﬁve  years  after  the  extension  of  vaccinations  to
ll children  using  acellular  vaccine  --  still  a  challenge.  The
cellular pertussis  vaccine  may  be  less  effective  than  the
hole-cell vaccine,  and  the  universal  use  of  pertussis  vac-
ines has  evidently  led  to  genetic  changes  in  the  circulating
. pertussis  strains.18 Therefore,  the  circulating  strains  and
vailable vaccines  need  continuous  evaluation  and  develop-
ent. The  cornerstones  of  the  work  against  whooping  cough
re effective  vaccines  and  extensive  vaccination  programs
ith high  coverage  rates.  In  the  future,  booster  vaccina-
ions through  the  whole  life  should  be  considered,  not  only
o prevent  disease  in  adults  but  also  to  prevent  the  disease
ransmission from  adults  to  infants.19 Clinical  and  epidemi-
logical studies,  as  well  as  clinical  drug  trials,  are  needed
o optimize  the  diagnostics  and  treatment.
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